Kangpu Announces First Patient Dosed in the US Phase IIa Clinical Trial of NeoMIDES™ Molecular Glue KPG-818 in Systemic Lupus Erythematosus ...Middle East

SHANGHAI, June 12, 2022 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company based in Shanghai, China, announced today that the first patient has been dosed in the Company's US Phase IIa clinical trial of KPG-818, an orally bioavailable NeoMIDESTM molecular glue, for the...

Hence then, the article about kangpu announces first patient dosed in the us phase iia clinical trial of neomides molecular glue kpg 818 in systemic lupus erythematosus was published today ( Monday 13/06/2022 - 04:28 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Kangpu Announces First Patient Dosed in the US Phase IIa Clinical Trial of NeoMIDES™ Molecular Glue KPG-818 in Systemic Lupus Erythematosus )

Also on site :

• This Guitarist Helped Shape One of the Most Iconic Sounds of the '90s
• John Travolta Directs Lookalike Daughter in New Film—and Fans Are Doing a Double Take
• I Tried 19 Frozen Pizzas—And the Winner Is a New Find That Won by a Landslide